Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1COVID-19 1

Interventions

Surveys and Questionnaires 6Standard of Care 6Blood Specimen Collection 6BNT162 Vaccine 5Hydroxychloroquine 4Surgical Procedures, Operative 3Specimen Handling 3Practice Guidelines as Topic 3COVID-19 Vaccines 32019-nCoV Vaccine mRNA-1273 3tocilizumab 2sotrovimab 2Pandemic Preparedness 2CVnCoV COVID-19 vaccine 2Azithromycin 2sinovac COVID-19 vaccine 1selinexor 1remdesivir 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1cilgavimab and tixagevimab drug combination 1ciclesonide 1avdoralimab 1XAV-19 1Therapeutics 1Telemedicine 1Sperm Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × COVID-19 × Ad26COVS1 × Clear all
NCT04930055 2023-05-19

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Indiana University

Terminated
2,206 enrolled

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡